JBC Oz Biosciences

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M311430200 on March 23, 2004

J. Biol. Chem., Vol. 279, Issue 22, 23098-23103, May 28, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/22/23098    most recent
M311430200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shi-wen, X.
Right arrow Articles by Abraham, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shi-wen, X.
Right arrow Articles by Abraham, D. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Endothelin-1 Induces Expression of Matrix-associated Genes in Lung Fibroblasts through MEK/ERK*

Xu Shi-wen{ddagger}, Sarah L. Howat§, Elisabetta A. Renzoni¶, Alan Holmes{ddagger}, Jeremy D. Pearson§, Michael R. Dashwood||, George Bou-Gharios**, Christopher P. Denton{ddagger}, Roland M. du Bois¶, Carol M. Black{ddagger}, Andrew Leask{ddagger}{ddagger}{ddagger}, and David J. Abraham{ddagger}

From the {ddagger}Centre for Rheumatology, Department of Medicine and the ||Department of Molecular Pathology, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom, the §Centre for Cardiovascular Biology and Medicine, Guy's, King's, and St. Thomas' School of Biomedical Sciences, King's College London, Guy's Campus, London, SE1 1UL, United Kingdom, the Interstitial Lung Disease Unit, Royal Brompton Hospital, Imperial College School of Medicine, London SW3 6LR, United Kingdom, **Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom

Received for publication, October 17, 2003 , and in revised form, March 22, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The endothelins are a family of endothelium-derived peptides that possess a variety of biological activities, including potent vasoconstriction. Endothelin-1 (ET-1) is up-regulated during tissue repair and pulmonary fibrosis. Here, we use genome-wide expression array analysis to show that the addition of ET-1 (100 nM, 4 h) to normal lung fibroblasts directly induces expression of matrix and matrix-associated genes, including the profibrotic protein CCN2 (connective tissue growth factor, or CTGF). ET-1 induces the MEK/ERK MAP kinase pathway in fibroblasts. Blockade of the MEK/ERK kinase pathway with U0126 abrogates the ability of ET-1 to induce expression of matrix and matrix-associated mRNAs and the CCN2 protein. The CCN2 promoter possesses an ET-1 response element, which maps to the previously identified basal control element-1 (BCE-1) site. Our results suggest that ET-1 induces a program of matrix synthesis in lung fibroblasts and that ET-1 may play a key role in connective tissue deposition during wound repair and in pulmonary fibrosis.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
As a response to environmental insults or a consequence of local inflammatory processes, structural damage to tissue can occur, triggering a wound-healing response. This response consists of an integrated series of biochemical, immunological, and structural changes that result in the de novo synthesis of a new epithelium, blood vessels, and connective tissue (1). The proper repair of connective tissue requires the synthesis and organization of new ECM1 components, such as collagen and fibronectin (2).

A growing body of evidence implicates the vasoconstrictive peptide endothelin-1 (ET-1) as a key mediator of tissue repair (3). Each of the three known endothelin isoforms (-1, -2, and -3) arise by proteolytic processing of large precursors (~200 amino acid residues). Intermediates, termed big ET-1, -2, and -3 (38-41 amino acids), are excised from pre-propeptides at sites containing paired basic amino acids. Big endothelins, which have little or no biological activity (4), are cleaved at Trp-21-Val/Ile-22 to produce mature, 21-residue, biologically active peptides (5, 6). The enzyme responsible for the specific cleavage at Trp-21 has been termed the endothelin-converting enzyme (7, 8). Injury and the wound-healing response lead to stabilization of endothelin-converting enzyme-1 mRNA and to the generation of bioactive endothelin (9). Elevated levels of ET-1 have been shown in patients with fibrotic disease, suggesting that ET-1 may play a key role not only in normal wound repair but also in the pathogenesis of fibrosis (10-14).

ET-1 demonstrates a wide range of biological properties, including significant mitogenic activity toward a number of cell types such as smooth muscle cells and fibroblasts (15). ET-1 also promotes the contractile ability of normal fibroblasts (16), which is essential for wound closure and reconstitution of the dermis (17). In addition, ET-1 modifies extracellular matrix metabolism (15, 18-20). For example, ET-1 enhances collagen types I and III and decreases matrix metalloproteinase-1 (MMP-1) mRNA and protein expression in dermal fibroblasts (18, 20). However, the signal transduction mechanism and transcription factors through which ET-1 affects gene expression is largely unknown. Furthermore, it is unclear to what extent ET-1 might contribute to wound repair or fibrogenic responses.

In this report, we investigate the functional and mechanistic contribution of ET-1 to matrix synthesis in primary human lung fibroblasts. Our results provide new insights into ET-1 biology and suggest a role for ET-1 in enhancing matrix expression and organization during tissue repair and fibrogenesis.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture—Primary human lung fibroblasts were grown from macroscopically and histologically normal lung resection specimens by explant culture as described previously (21) using DMEM with 10% fetal bovine serum (Invitrogen). Cells were used between passages 2 and 5.

Gene Array Analysis—Lung fibroblasts were serum starved for 18 h and treated with 100 nM ET-1 for 4 h. At the end of the treatment period, total RNA was harvested (Trizol; Invitrogen) and quantified, and integrity was verified by denaturing gel electrophoresis. Equal amounts of identically treated RNA were pooled and reverse transcribed (Invitrogen) into cDNA, which was then in vitro transcribed into biotinylated cRNA. The target cRNA was then fragmented and hybridized to the Affymetrix human U133A array following Affymetrix (Santa Clara, CA) protocol. Hybridization of cRNA to Affymetrix human U133A chips, signal amplification, and data collection were performed using an Affymetrix fluidics station and chip reader. Chip files were scaled to an average intensity of 100 per gene and analyzed using the Affymetrix version 5.0 (MAS5) comparison analysis software. Experiments were performed twice, and the fold changes presented in Table I are an average of these independent studies. Criteria indicated by Affymetrix were used to determine robust changes in gene expression. Briefly, transcripts were defined as up-regulated by ET-1 only when identified as "present" (ET-1-treated chips) by the Affymetrix detection algorithm and "significantly increased," as determined by the Affymetrix change algorithm, with a change p value of <0.01. The fold change between treated and untreated samples had to be at least 1.5-fold to identify a transcript as being altered. These criteria had to be met in both sets of experiments. We have entered one experiment (ET-1 untreated/treated) in the NCBI Gene Expression Omnibus (GEO) as samples GSM15500 [NCBI GEO] and GSM15501 [NCBI GEO] , and the other experiment has been entered as GSM17262 [NCBI GEO] and GSM17263 [NCBI GEO] . The GEO series, including all samples, has been entered as GSE1081 [NCBI GEO] (www.ncbi.nlm.nih.gov/geo).


View this table:
[in this window]
[in a new window]
  		TABLE I
Transcripts induced in human lung fibroblasts after treatment with 100 nM endothelin-1 for 4 h

 
Western Blot Analysis—Lung fibroblasts were grown to confluence in DMEM with 10% fetal bovine serum and cultured in DMEM and 0.5% bovine serum albumin for 24 h. To ascertain the effect of ET-1 on CCN2 (connective tissue growth factor, or CTGF) expression, cells were stimulated with 100 nM ET-1 for 48 h with 0.5% bovine serum albumin treatment. To assess the effect of ET-1 on the stimulation of signaling pathways, ET-1 was added to cells for up to 16 h. When appropriate, cells were incubated with an inhibitor for 45 min prior to the addition of ET-1. The activities of inhibitors were verified by examining their ability to block phosphorylation of Akt or by assessing their ability to block induction of promoters responsive to particular signaling cascades (Clontech). Cell layer lysates were subjected to SDS-PAGE and electroblotted onto nitrocellulose membranes. CCN2 protein was detected using an anti-CCN2 (CTGF) antibody (Santa Cruz Biotechnology), and the glyceraldehyde-3-phosphate (GAPDH) protein was detected using an anti-GAPDH antibody (Santa Cruz Biotechnology). Akt, phospho-Akt, p38, phospho-p38, p42/44 MAPK, and phospho-p42/44 MAPK were detected using antibodies as described by the manufacturer (Cell Signaling Technology, Beverly, MA). Blots were then hybridized with an appropriate horseradish peroxidase-conjugated secondary antibody (Jackson ImmunoResearch Laboratories), and protein was detected using chemiluminescence (Amersham Biosciences).

Promoter Assays—CCN2 promoter/secreted enhanced alkaline phosphatase (SEAP) reporter constructs were as described previously (25, 26). Promoter/reporter constructs were transfected into lung fibroblasts using FuGENE6 transfection reagent (Roche Applied Science) according to the manufacturer's instructions. Promoter/reporter plasmids were cotransfected with pCMV-{beta}Gal (Clontech), which was used to adjust for differences in transfection efficiencies between samples. Following transfection, cells were incubated in DMEM with 0.5% fetal bovine serum for 18 h. Media were changed, and cells were incubated in the presence or absence of inhibitors for 45 min and cultured for an additional 24 h in the presence or absence of ET-1 (100 nM). Media were taken for SEAP assays. Fibroblasts were rinsed once with phosphate-buffered saline, and cellular protein was extracted using 200 µl of reporter lysis buffer (Promega Corp, Madison, WI). Reporter gene activity was measured by luminometry (Turner Designs, Sunnyvale, CA) using SEAP and {beta}-galactosidase assays (Tropix Inc. Bedford, MA) according to the manufacturers' instructions. Values given are mean ± S.E. of triplicate assays from three individual experiments.

Reverse Transcription PCR—Lung fibroblasts were serum-starved for 18 h and treated with 100 nM ET-1 for 2, 4, or 12 h. Total RNA was isolated using Trizol (Invitrogen), and the integrity of the RNA was verified by gel electrophoresis. Total RNA (10 µg) was reverse transcribed in a 20-µl reaction volume containing an oligonucleotide (dT18) and random decamers (dN10) using M-MLV reverse transcriptase (Promega) for 1 h at 37 °C. The cDNA was diluted to 100 µl with diethylpyrocarbonate-treated water, and the target was measured by real time PCR FastStart DNA Master SYBR Green (Roche Applied Science) according to the manufacturer's instructions. Triplicate samples were run, transcripts were measured in picograms, and expression values were standardized to values obtained with control 28 S RNA primers. Primers (Sigma Genosys) were as follows: COL4A1, 5'-ATAGGTTTCCCAGGGCAGC3-' (forward) and 5'-CCACGCTCTCCTTCAATCC-3' (reverse); TSP1, 5'-CAGCTGGAAATGTGGTGCTTGT-3' (forward) and 5'-CGTGGCATGTTCGACACCCT-3' (reverse); TIMP3, 5'-GGCAGCAAGCAGATAGACTC-3' (forward) and 5'-GTGCTTGCTCCAGACTCAG-3' (reverse); CCN2, 5'-CTCGCGGCTTACCGACTG-3' (forward) and 5'-GCACTTGAACTCCACCGG-3' (reverse); MMP-1, 5'-TCACCAAGGTCTCTGAGGGTCAAGC-3' (forward) and 5'-GGATGCCATCAATGTCATCCTGAGC-3' (reverse); and 28 S, 5'-TTGAAAATCCGGGGGAGAG-3' (forward) and 5'-ACATTGTTCCAACATGCCAG-3' (reverse).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Global Expression Profiling in Response to ET-1—To identify transcripts induced by ET-1, we treated primary lung fibroblasts for 4 h in the presence or absence of 100 nM ET-1. After this period of incubation, we harvested total RNA. Affymetrix U133A gene arrays were hybridized to these labeled cRNAs derived from the total RNA. Gene array analysis revealed that a 4-h treatment of primary lung fibroblasts with ET-1-modified expression of a cluster of transcripts encoding proteins that would be expected to promote matrix deposition and remodeling (Table I). ET-1 treatment induced expression of the matrix protein collagen types IV, V, and VII (27). ET-1 treatment also induced expression of the collagen-modifying enzyme lysyl oxidase (28) and the pro-adhesive and pro-fibrotic gene CCN2 (CTGF) (29). ET-1 also induced thrombospondin-1, a multifunctional matricellular protein that promotes the function of many molecules involved with the wound-healing response, including transforming growth factor-{beta} (TGF{beta}) (30), matrix metalloproteinases (31), and focal adhesions (32). In addition, ET-1 induced expression of the tissue inhibitor of matrix metalloprotenases-3 (TIMP-3) and MMP-1 and -3, which adjust and control levels of matrix deposition (33). Other than MMP-1, all genes revealed by our transcriptional profiling are novel targets of ET-1 in fibroblasts (Table I).

ET-1 Enhances CCN2 Expression through a MEK/ERK-dependent Mechanism—CCN2 (CTGF) is an important profibrotic protein that induces collagen and acts with TGF{beta} to promote sustained fibrosis in vivo (29, 34). Because our array analysis showed that CCN2 mRNA was induced by ET-1 treatment, we sought to explore the notion that ET-1 might contribute to fibrotic responses in vivo through the induction of CCN2. Thus, we treated normal lung fibroblasts for 24 h with 100 nM ET-1. Cell layers were harvested, and equal amounts of protein (20 µg) were subjected to Western blot analysis with an anti-CCN2 antibody. Confirming our microarray data, we found that 100 nM ET-1 induced expression of CCN2 protein (Fig. 1).



View larger version (75K):
[in this window]
[in a new window]
  		FIG. 1.
ERK1/2 inhibitors significantly attenuate the ET-1-mediated induction of CCN2 protein. Top panel, normal lung fibroblasts were serum-starved for 18 h and then incubated for an additional 24 h with ET-1 (100 nM). Whole cell protein extracts were made, and equal amounts of protein were subjected to SDS/PAGE by Western blot analysis with an anti-CCN2 antibody (see "Materials and Methods"). ET-1 induced CCN2 protein expression, which was completely abolished by co-incubation with the mixed ETA/B receptor antagonist bosentan (Bos; 10 µM) and the MEK inhibitors U0126 (U; 10 µM) and PD98059 (PD; 30 µM). SB203580 (SB; 30 µM), wortmannin (W; 10 µM), and LY294002 (Ly; 10 µM) had no appreciable effect on CCN2 expression. Bottom panel, to verify specificity of inhibitors used, cells were treated for ET-1 for the time indicated in the presence or absence of inhibitors as denoted in the top panel. Protein extracts were then prepared and subjected to Western blot analysis with anti-Akt and anti-phospho Akt antibodies. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

 
To begin to probe the signaling mechanism through which ET-1 induced CCN2, we performed Western blot analysis of protein extracts prepared from lung fibroblasts that had been treated with ET-1 for different lengths of time. Using anti-phospho-ERK, anti-phospho-p38, and anti-phospho-Akt antibodies, we showed that ET-1 activated ERK (p42/p44), p38, and PI3-kinase/Akt pathways in lung fibroblasts (Fig. 2). To address the contribution of these pathways to the ET-1 induction of CCN2, we used Western blot analysis with an anti-CCN2 antibody to show that a 45-min pre-incubation with the MEK/ERK inhibitors PD98059 and U0126 (35, 36), prior to the addition of ET-1, blocked the ability of ET-1 to induce CCN2 protein (Fig. 1, bottom panel). Conversely, the addition of the p38 inhibitor SB203580 (37) or the Akt/PI-3-kinase inhibitors wortmannin and LY294002 (38, 39) had no discernible effect on the ability of ET-1 to modulate CCN2 production. In addition, a 45-min preincubation of lung fibroblasts with the dual specificity ETA/B receptor antagonist bosentan (40) blocked the ability of ET-1 to induce CCN2 (Fig. 1). Thus, ET-1 stimulated CCN2 protein expression in normal human lung fibroblasts through a MEK/ERK-dependent mechanism that required either the ETA or the ETB receptor.



View larger version (14K):
[in this window]
[in a new window]
  		FIG. 2.
ET-1 induces p38 MAPK, p42/44 MAPK, and Akt phosphorylation in normal primary lung fibroblasts. Normal lung fibroblasts were cultured, serum-starved for 18 h, and treated with 100 nM ET-1. Whole cell protein extracts were made, and equal amounts of protein were subjected to SDS/PAGE and Western blot analysis with anti-ERK, anti-phospho-ERK, anti-p38, anti-phospho-p38, anti-Akt, and anti-phospho-Akt antibodies. Treatment of lung fibroblasts with ET-1 induces all three pathways tested.

 
ET-1 Modifies Expression of Fibrogenic Genes in a MEK/ERK-dependent Mechanism—After determining that ET-1 induced CCN2 protein through a MEK/ERK-dependent mechanism, we decided to investigate further the contribution of MEK/ERK to ET-1 induced gene expression. Using real time polymerase chain reaction analysis, we confirmed that ET-1 induced MMP-1, CCN2, collagen IV, TSP-1, and TIMP-3 mRNAs (Fig. 3). Induction of MMP-1, CCN2, TSP-1, and TIMP-3 seemed to be direct, showing potent induction 2 h after the application of ET-1. To determine whether ET-1 induced these transcripts via a MEK/ERK-dependent mechanism, cells were pre-incubated for 45 min with or without the MEK/ERK MAP kinase inhibitor U0126 (10 µM) prior to the addition of ET-1. We found that pre-incubation of cells with U0126 potently inhibited the ability of ET-1 to induce MMP-1, CCN2, collagen IV, TSP-1, and TIMP-3 mRNA expression. Thus, ET-1 is a potent fibrogenic peptide, able to induce mRNA expression of matrix genes in lung fibroblasts via MEK/ERK.



View larger version (9K):
[in this window]
[in a new window]
  		FIG. 3.
ET-1 induces transcription of matrix genes by a MEK/ERK-dependent mechanism. Reverse transcription PCR was used to detect MMP-1, CCN2, collagen type IV, TSP-1, TIMP-3, and 28 S RNA as indicated Expression values of ECM genes are expressed as a ratio relative to 28 S RNA. After incubation for 45 min with or without the MEK1/2 inhibitor U0126 (10 µM), fibroblasts were treated with or without 100 nM ET-1 for 2, 4, or 12 h. Total RNA was extracted, purified, and reverse transcribed into cDNA and amplified with specific primers (see "Materials and Methods") to detect the expression of particular ECM genes. All assays were performed in triplicate. Solid lines, ET-treated cells; dotted lines, untreated cells; dashed lines, ET plus U0126.

 
ET-1 Activates the CCN2 Promoter through the BCE-1 Element—After establishing that ET-1 induced the appearance of CCN2 protein and mRNA in lung fibroblasts, we sought to investigate further the mechanism through which ET-1 performs this function. For these experiments, we assessed whether an ET-1 response element existed in the CCN2 promoter. To perform this experiment, we transfected a full-length CCN2 promoter/SEAP reporter construct, spanning nucleotides -805 to +17 of the CCN2 promoter (Fig. 4, -805; Ref. 26), into lung fibroblasts. After an 18-h serum starvation step, cells were cultured in the presence or absence of 100 nM ET-1 for an additional 24 h. Consistent with our data showing that ET-1 induced CCN2 protein and mRNA expression, we found that ET-1 induced CCN2 promoter activity (Fig. 4). To further delineate the ET-1 response element in the CCN2 promoter, we transfected two additional CCN2 promoter/SEAP reporter constructs into fibroblasts. These new constructs contained segments of the CCN2 promoter spanning nucleotides -244 to +17 (Fig. 4, -244) or -86 to +17 (Fig. 4, -86; Ref. 26). We found that, although the fragment of the CCN2 promoter between -244 to +17 could respond to ET-1, the removal of nucleotides -244 to -86 abolished the ability of the CCN2 promoter to respond to ET-1 (Fig. 4). Thus, the ET-1 response element in the CCN2 promoter lay between nucleotides -244 and -86.



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 4.
ET-1 induces the CCN2 promoter through the BCE-1 element. Fibroblasts were transiently transfected with DNA reporter constructs containing different fragments, as indicated, of the human CCN2 promoter sequences inserted upstream of a SEAP reporter gene (22, 23). Results shown are for three individual experiments with three replicates per experiment. Values given are expressed as mean ± S.D. -805, a construct containing nucleotides -805 to + 17 of the CCN2 promoter; -244, a construct containing nucleotides -244 to +17 of the CCN2 promoter; -86, a construct containing nucleotides -86 to +17 of the CCN2 promoter; -805 Smad, a construct containing a mutation in the Smad binding element of the CCN2 promoter; -805 BCE-1, a construct containing a mutation in the BCE-1 binding element of the CCN2 promoter. These latter two mutations were made in the context of the larger -805 construct.

 
Previously, we had analyzed the transcription factor binding sites lying between nucleotides -244 and -86 of the CCN2 promoter and identified a Smad binding element, which is required for the TGF{beta}-induction of CCN2, and a basal control element-1 (BCE-1) site, which is required for basal CCN2 expression but is not involved with the TGF{beta}-induction of CCN2 (25). To assess the roles of Smad and BCE-1 elements in the ET-1 induction of the CCN2 promoter, we transfected into lung fibroblasts constructs that contained mutations in the Smad and BCE-1 elements of the CCN2 promoter (Smad and BCE-1, respectively, Fig. 4) but were otherwise identical to the full-length (-805 to +17) CCN2 promoter construct. We found that removal of the Smad element had no significant impact on the ability of the CCN2 reporter to respond to ET-1 (Fig. 4, -805 Smad). Conversely, removal of the BCE-1 element abolished the response of the CCN2 promoter to ET-1 (Fig. 4, -805 BCE-1). Thus, ET-1 promotes CCN2 expression in a fashion that is independent of Smad/TGF{beta} signaling but dependent on BCE-1. These results suggest that ET-1 promotes gene expression in a manner that is independent of TGF{beta}.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, we used primary human lung fibroblasts as an in vitro model with which to probe the role of ET-1 in ECM production. Previously, we have shown that ET-1 enhances collagen types I and III and decreases MMP-1 mRNA and protein expression in dermal fibroblasts (18, 20). In this report, we extend these results by showing that ET-1 in itself is capable of inducing the expression of ECM or ECM-associated genes. ET-1 induced collagen type IV, a key basement membrane component (41). ET-1 induced collagen type VII, the major component of anchoring fibrils that attach epidermis and dermis; mutations in the COL7A1 gene encoding type VII collagen cause a severe blistering disease, dystrophic epidermolysis bullosa (42). In addition, ET-1 induces collagen type V, which interacts with collagen type I to regulate the diameters of type I collagen fibrils (43). Thus, by the ability of ET-1 to induce collagens IV, V, and VII, ET-1 promotes the wound-healing response by enhancing reconstitution of the basement membrane and wound closure.

ET-1 induces CCN2, a member of the CCN family of proteins (44, 45). CCN2 is a cysteine-rich, pro-adhesive, matricellular protein that plays an essential role in the formation of blood vessels, bone, and connective tissue (46). Because the expression of this protein is potently induced by TGF{beta} in a Smad-dependent fashion (22), it has been hypothesized that CCN2 mediates several of the downstream actions of TGF{beta} (26). Ours is the first report to show that ET-1 induces CCN2 and, thus, that CCN2 could also be a downstream mediator of ET-1 activity. The ET-1 response element of the CCN2 promoter is independent of its Smad element, which is required for the TGF{beta}-induction of CCN2 (22, 47). Instead, the ET-1 induction of CCN2 occurs through the BCE-1 element of the CCN2 promoter, which is not required for the TGF{beta}-induction of CCN2 (22). These results suggest that TGF{beta} and ET-1 might work independently on the CCN2 promoter to elevate CCN2 expression in vivo and, thus, that TGF{beta} and ET-1 might cooperate to produce fibrogenic responses in vivo thorough the coordinate induction of CCN2 (Fig. 5). The identity of the factor(s) binding to the BCE-1 site of the CCN2 promoter is not known but is currently under investigation.



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 5.
Schematic diagram showing that ET-1 contributes to ECM synthesis in lung fibroblasts. ET-1 promotes ECM synthesis in normal and lung fibroblasts through MEK/ERK kinase. ET-1 also induces expression of the profibrotic protein CCN2, which induces matrix synthesis (49, 50). ET-1 also induces thrombospondin-1 (30), a potent activator of TGF{beta}, a key inducer of ECM production and fibrotic responses (61, 62).

 
It is interesting to note that we have shown previously that a 48-h treatment of normal dermal fibroblasts with ET-1 caused the induction of collagen type I mRNA (20). In this report, using normal lung fibroblasts, our transcriptional profiling using the Affymetrix system showed that ET-1 did not induce collagen type I mRNA after 4 h. Using real time PCR, we confirmed that ET-1 induced type I collagen mRNA commencing 6 h after ET-1 treatment (not shown). Collectively, these results suggest that the ability of ET-1 to induce type I collagen might be indirect. However, in this report we showed appreciable induction of CCN2 and thrombospondin-1 mRNA 2 h after ET-1 treatment. CCN2 induces type I collagen (29, 48, 49), and thrombospondin-1 activates latent TGF{beta} (30, 50). Thus, the ability of ET-1 to induce collagen type I expression may be indirect, possibly via the induction of CCN2 or by the activation of latent TGF{beta} (Fig. 5). It is interesting to note that, in endothelial cells, TGF{beta} induces ET-1 expression via Smad and Ap-1 sites in the ET-1 promoter (51). Although TGF{beta} has been shown to be a key pro-fibrotic cytokine, its action can be amplified or suppressed by several other cytokines (52). Understanding the interactions among these profibrotic and anti-fibrotic cytokines is likely to have a major impact in understanding wound-healing and fibrotic responses in vivo. Thus, further research elucidating the mechanism by which ET-1, TGF{beta} and CTGF might interact to promote pro-fibrotic responses is of major importance.

Because ET-1 is markedly up-regulated during tissue repair (9) and in patients with fibrotic disease, these results suggest that ET-1 may play a key role not only in normal wound repair but also in the pathogenesis of fibrosis (10-14). Elevated levels of circulating ET-1 occurred in patients with skin and lung fibrosis, a finding that correlated with the severity of the fibrotic phenotype (53-55). This increase in circulating ET-1 was paralleled by an increase in ET-1 synthesis in vivo (53-55). Thus, ET-1 may be an important therapeutic target in the modulation of fibrogenesis. Indeed, our data suggest that ET-1 is a potent fibrogenic peptide for lung fibroblasts, able to induce matrix production by lung fibroblasts via a MEK/ERK-dependent mechanism requiring either the ETA or the ETB receptors (Fig. 5).

The results presented in this report are consistent with several studies published recently that have linked the p42/p44 (MEK/ERK) MAP kinase signaling cascade and fibrosis. For example, the TGF{beta} induction of CCN2 requires the ras/MEK/ERK signaling cascade (47, 56, 57). Recently, we showed that the synthetic prostacyclin iloprost, which alleviates symptoms of fibrosis in patients with the fibrotic disease systemic sclerosis (49), works, at least in part, through the antagonism of the MEK/ERK pathway (57). Collectively, our results suggest that the antagonism of MEK/ERK might be an effective anti-fibrotic approach.

In summary, the results presented in our current report emphasize that ET-1 is an important regulator of extracellular matrix biosynthesis by lung fibroblasts and further emphasize the key role of the MEK/ERK cascade in tissue injury and wound healing. Our results further suggest that there may be a potential therapeutic advantage in using MEK/ERK kinase inhibitors or endothelin antagonists to ameliorate the pathological scarring observed in pulmonary fibrosis.


   FOOTNOTES
 
The Gene Expression Omnibus(GEO) series number for the expression data of this work is GSE1081 [NCBI GEO] .

* This work was supported by the Raynaud's and Scleroderma Association Trust, the Scleroderma Foundation, the Wellcome Trust, the Arthritis Research Campaign, the Nightingale Trust, the Welton Foundation, and the British Heart Foundation. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger}{ddagger} To whom correspondence should be addressed. Tel.: 207-794-0500 ext. 4053; Fax: 207-794-0432; E-mail: a.leask{at}rfc.ucl.ac.uk.

1 The abbreviations used are: ECM, extracellular matrix; CTGF, connective tissue growth factor; DMEM, Dulbecco's modified Eagle's medium; ET, endothelium; ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; MMP, matrix metalloproteinase; SEAP, secreted enhanced alkaline phosphatase; TGF, transforming growth factor; TIMP, tissue inhibitor of matrix metalloproteinase. Back


   ACKNOWLEDGMENTS
 
We thank Gary Grotendorst (University of Miami) for providing an initial CTGF promoter construct.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Werner, S., and Grose, R. (2003) Physiol. Rev. 83, 835-870[Abstract/Free Full Text]
  2. Badylak, S. F. (2002) Semin. Cell Dev. Biol. 13, 377-383[CrossRef][Medline] [Order article via Infotrieve]
  3. Bull, H. A., and Dowd, P. M. (1993) Dermatology 187, 1-5[Medline] [Order article via Infotrieve]
  4. Yanagisawa, M. (1994) Circulation 89, 1320-1322[Free Full Text]
  5. Anggard, E. E., Botting, R. M., and Vane, J. R. (1990) Blood Vessels 27, 269-281[Medline] [Order article via Infotrieve]
  6. Rubanyi, G. M., and Botelho, L. H. (1991) FASEB J. 5, 2713-2720[Abstract]
  7. Ohnaka, K., Takayanagi, R., Nishikawa, M., Haji, M., and Nawata, H. (1993) J. Biol. Chem. 268, 26759-26766[Abstract/Free Full Text]
  8. Turner, A. J., and Murphy, L. J. (1996) Biochem. Pharmacol. 51, 91-102[CrossRef][Medline] [Order article via Infotrieve]
  9. Shao, R., Shi, Z., Gotwals, P. J., Koteliansky, V. E., George, J., and Rockey, D. C. (2003) Mol. Biol. Cell 14, 2327-2341[Abstract/Free Full Text]
  10. Vancheeswaran, R., Magoulas, T., Efrat, G., Wheeler-Jones, C., Olsen, I., Penny, R., and Black, C. M. (1994) J. Rheumatol. 21, 1838-1844[Medline] [Order article via Infotrieve]
  11. Kohan, D. E. (1997) Am. J. Kidney Dis. 29, 2-26[Medline] [Order article via Infotrieve]
  12. Teder, P., and Noble, P. W. (2000) Am. J. Respir. Cell Mol. Biol. 23, 7-10[Free Full Text]
  13. Kinnman, N., and Housset, C. (2002) Front Biosci. 7, d496-d503[Medline] [Order article via Infotrieve]
  14. Simms, R. W., and Korn, J. H. (2002) Curr. Opin. Rheumatol. 14, 717-722[CrossRef][Medline] [Order article via Infotrieve]
  15. Levin, E. R. (1995) N. Engl. J. Med. 333, 356-363[Free Full Text]
  16. Guidry, C., and Hook, M. (1991) J. Cell Biol. 115, 873-880[Abstract/Free Full Text]
  17. Grinnell, F. (1994) J. Cell Biol. 124, 401-404[Free Full Text]
  18. Xu, S., Denton, C. P., Holmes, A., Dashwood, M. R., Abraham, D. J., and Black, C. M. (1998) J. Cardiovasc. Pharmacol. 31, Suppl. 1, S360-S363[Medline] [Order article via Infotrieve]
  19. Saita, Y., Yazawa, H., Koizumi, T., Morita, T., Tamura, T., Takenaka, T., and Honda, K. (1998) Eur. J. Pharmacol. 349, 123-128[CrossRef][Medline] [Order article via Infotrieve]
  20. Shi-Wen, X., Denton, C. P., Dashwood, M. R., Holmes, A. M., Bou-Gharios, G., Pearson, J. D., Black, C. M., and Abraham, D. J. (2001) J. Invest Dermatol. 116, 417-425[CrossRef][Medline] [Order article via Infotrieve]
  21. Shi-Wen, X., Denton, C. P., McWhirter, A., Bou-Gharious, G., Abraham, D. J., du Bois, R. M., and Black, C. M. (1997) Arthritis Rheum. 40, 1237-1244[Medline] [Order article via Infotrieve]
  22. Hakonarson, H., Halapi, E., Whelan, R., Gulcher, J., Stefansson, K., and Grunstein, M. M. (2001) Am. J. Respir. Cell Mol. Biol. 25, 761-771[Abstract/Free Full Text]
  23. Taddeo, B., Esclatine, A., and Roizman, B. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 17031-17036[Abstract/Free Full Text]
  24. Deleted in proof
  25. Holmes, A., Abraham, D. J., Sa, S., Shiwen, X., Black, C. M., and Leask, A. (2001) J. Biol. Chem. 276, 10594-10601[Abstract/Free Full Text]
  26. Abraham, D. J., Shiwen, X., Black, C. M., Sa, S., Xu, Y., and Leask, A. (2000) J. Biol. Chem. 275, 15220-15225[Abstract/Free Full Text]
  27. Handford, P. A. (2000) Biochim. Biophys. Acta 1498, 84-90[Medline] [Order article via Infotrieve]
  28. Reiser, K., McCormick, R. J., and Rucker, R. B. (1992) FASEB J. 6, 2439-2449[Abstract]
  29. Leask, A., Denton, C. P., and Abraham, D. J. (2004) J. Investig. Dermatol. 122, 1-6[CrossRef][Medline] [Order article via Infotrieve]
  30. Crawford, S. E., Stellmach, V., Murphy-Ullrich, J. E., Ribeiro, S. M., Lawler, J., Hynes, R. O., Boivin, G. P., and Bouck, N. (1998) Cell 93, 1159-1170[CrossRef][Medline] [Order article via Infotrieve]
  31. Baker, A. H., Edwards, D. R., and Murphy, G. (2002) J. Cell Sci. 115, 3719-3727[Abstract/Free Full Text]
  32. Murphy-Ullrich, J. E. (2001) J. Clin. Investig. 107, 785-790[CrossRef][Medline] [Order article via Infotrieve]
  33. Okada, T., Sakuma, L., Fukui, Y., Hazeki, O., and Ui, M. (1994) J. Biol. Chem. 269, 3563-3567[Abstract/Free Full Text]
  34. Mori, T., Kawara, S., Shinozaki, M., Hayashi, N., Kakinuma, T., Igarashi, A., Takigawa, M., Nakanishi, T., and Takehara, K. (1999) J. Cell. Physiol. 181, 153-159[CrossRef][Medline] [Order article via Infotrieve]
  35. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7686-7689[Abstract/Free Full Text]
  36. Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., Copeland, R. A., Magolda, R. L., Scherle, P. A., and Trzaskos, J. M. (1998) J. Biol. Chem. 273, 18623-18632[Abstract/Free Full Text]
  37. Cuenda, A., Rouse, J., Doza, Y. N., Meier, R., Cohen, P., Gallagher, T. F., Young, P. R., and Lee, J. C. (1995) FEBS Lett. 364, 229-233[CrossRef][Medline] [Order article via Infotrieve]
  38. Arcaro, A., and Wymann, M. P. (1993) Biochem. J. 296, 297-301[Medline] [Order article via Infotrieve]
  39. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. (1994) J. Biol. Chem. 269, 5241-5248[Abstract/Free Full Text]
  40. Teerlink, J. R., Loffler, B. M., Hess, P., Maire, J. P., Clozel, M., and Clozel, J. P. (1994) Circulation 90, 2510-2518[Abstract/Free Full Text]
  41. Neubauer, K., Saile, B., and Ramadori, G. (2001) Can. J. Gastroenterol. 15, 187-193[Medline] [Order article via Infotrieve]
  42. Ryynanen, M., Ryynanen, J., Sollberg, S., Iozzo, R. V., Knowlton, R. G., and Uitto, J. (1992) J. Clin. Investig. 89, 974-980[Medline] [Order article via Infotrieve]
  43. Birk, D. E., Fitch, J. M., Babiarz, J. P., Doane, K. J., and Linsenmayer, T. F. (1990) J. Cell Sci. 95, 649-657[Abstract/Free Full Text]
  44. Leask, A., and Abraham, D. J. (2003) Biochem. Cell Biol. 81, 355-363[CrossRef][Medline] [Order article via Infotrieve]
  45. Brigstock, D. R. (2003) J. Endocrinol. 178, 169-175[Abstract]
  46. Ivkovic, S., Yoon, B. S., Popoff, S. N., Safadi, F. F., Libuda, D. E., Stephenson, R. C., Daluiski, A., and Lyons, K. M. (2003) Development 130, 2779-2791[Abstract/Free Full Text]
  47. Leask, A., Holmes, A., Black, C. M., and Abraham, D. J. (2003) J. Biol. Chem. 278, 13008-13015[Abstract/Free Full Text]
  48. Grotendorst, G. R. (1997) Cytokine Growth Factor Rev. 8, 171-179[CrossRef][Medline] [Order article via Infotrieve]
  49. Stratton, R., Shiwen, X., Martini, G., Holmes, A., Leask, A., Haberberger, T., Martin, G. R., Black, C. M., and Abraham, D. (2001) J. Clin. Investig. 108, 241-250[CrossRef][Medline] [Order article via Infotrieve]
  50. Schultz-Cherry, S., Ribeiro, S., Gentry, L., and Murphy-Ullrich, J. E. (1994) J. Biol. Chem. 269, 26775-26782[Abstract/Free Full Text]
  51. Rodriguez-Pascual, F., Redondo-Horcajo, M., and Lamas, S. (2003) Circ. Res. 92, 1288-1295[Abstract/Free Full Text]
  52. Leask, A., and Abraham, D. J. (2004). FASEB J., in press
  53. Yamani, K., Miyauchi, T., Suzuki, N., Yuhara, T., Akama, T., Suzuki, H., and Kashiwagi, H. (1992) J. Rheumatol. 19, 1566-1571[Medline] [Order article via Infotrieve]
  54. Kawaguchi, Y., Suzuki, K., Hara, M., Hidaka, T., Ishizuka, T., Kawagoe, M., and Nakamura, H. (1994) Ann. Rheum. Dis. 53, 506-510[Abstract/Free Full Text]
  55. Abraham, D. J., Vancheeswaran, R., Dashwood, M. R., Pantelides, P., Shi-wen, X., du Bois, R. M., and Black, C. M. (1997) Am. J. Pathol. 151, 831-841[Abstract]
  56. Chen, Y., Blom, I. E., Sa, S., Goldschmeding, R., Abraham, D. J., and Leask A. (2002) Kidney Int. 62, 1149-1159[CrossRef][Medline] [Order article via Infotrieve]
  57. Stratton, R., Rajkumar, V., Ponticos, M., Nichols, B., Shiwen, X., Black, C. M., Abraham, D. J., and Leask, A. (2002) FASEB J. 16, 1949-1951[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
A. Leask
TGF{beta}, cardiac fibroblasts, and the fibrotic response
Cardiovasc Res, May 1, 2007; 74(2): 207 - 212.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Pannu, S. Nakerakanti, E. Smith, P. t. Dijke, and M. Trojanowska
Transforming Growth Factor-beta Receptor Type I-dependent Fibrogenic Gene Program Is Mediated via Activation of Smad1 and ERK1/2 Pathways
J. Biol. Chem., April 6, 2007; 282(14): 10405 - 10413.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
C. Castanares, M. Redondo-Horcajo, N. Magan-Marchal, P. ten Dijke, S. Lamas, and F. Rodriguez-Pascual
Signaling by ALK5 mediates TGF-beta-induced ET-1 expression in endothelial cells: a role for migration and proliferation
J. Cell Sci., April 1, 2007; 120(7): 1256 - 1266.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
A. Leask and D. J. Abraham
All in the CCN family: essential matricellular signaling modulators emerge from the bunker
J. Cell Sci., December 1, 2006; 119(23): 4803 - 4810.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Liao, A. Schneider, N. S. Datta, and L. K. McCauley
Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis.
Cancer Res., September 15, 2006; 66(18): 9065 - 9073.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. S. Nakerakanti, B. Kapanadze, M. Yamasaki, M. Markiewicz, and M. Trojanowska
Fli1 and Ets1 Have Distinct Roles in Connective Tissue Growth Factor/CCN2 Gene Regulation and Induction of the Profibrotic Gene Program
J. Biol. Chem., September 1, 2006; 281(35): 25259 - 25269.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
X. Shi-Wen, F. Rodriguez-Pascual, S. Lamas, A. Holmes, S. Howat, J. D. Pearson, M. R. Dashwood, R. M. du Bois, C. P. Denton, C. M. Black, et al.
Constitutive ALK5-Independent c-Jun N-Terminal Kinase Activation Contributes to Endothelin-1 Overexpression in Pulmonary Fibrosis: Evidence of an Autocrine Endothelin Loop Operating through the Endothelin A and B Receptors.
Mol. Cell. Biol., July 1, 2006; 26(14): 5518 - 5527.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
P. Roestenberg, F. A. van Nieuwenhoven, J. A. Joles, C. Trischberger, P. P. Martens, N. Oliver, J. Aten, J. W. Hoppener, and R. Goldschmeding
Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice
Am J Physiol Renal Physiol, June 1, 2006; 290(6): F1344 - F1354.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Shi-wen, L. A. Stanton, L. Kennedy, D. Pala, Y. Chen, S. L. Howat, E. A. Renzoni, D. E. Carter, G. Bou-Gharios, R. J. Stratton, et al.
CCN2 Is Necessary for Adhesive Responses to Transforming Growth Factor-beta1 in Embryonic Fibroblasts
J. Biol. Chem., April 21, 2006; 281(16): 10715 - 10726.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
Y. Chen, X. Shi-wen, J. van Beek, L. Kennedy, M. McLeod, E. A. Renzoni, G. Bou-Gharios, S. Wilcox-Adelman, P. F. Goetinck, M. Eastwood, et al.
Matrix Contraction by Dermal Fibroblasts Requires Transforming Growth Factor-{beta}/Activin-Linked Kinase 5, Heparan Sulfate-Containing Proteoglycans, and MEK/ERK: Insights into Pathological Scarring in Chronic Fibrotic Disease
Am. J. Pathol., December 1, 2005; 167(6): 1699 - 1711.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. Zhou, C. Li, and L. Cai
Advanced Glycation End-Products Induce Connective Tissue Growth Factor-Mediated Renal Fibrosis Predominantly through Transforming Growth Factor {beta}-Independent Pathway
Am. J. Pathol., December 1, 2004; 165(6): 2033 - 2043.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/22/23098    most recent
M311430200v1
Right arrow Alert me when this article is cited
Right arrow